专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明公开

KR1020090016595A 항균성 펩티드의 발현을 회복시키기 위한 스핑고실포스포릴콜린 길항제의 용도 有权
标题翻译：用于恢复抗微生物肽表达的SPHINGOSYLPHOSPHORLCHOLINE ANTAGONIST的使用
公开(公告)号：KR1020090016595A
公开(公告)日：2009-02-16
申请号：KR1020087030865
申请日：2006-12-08
申请人： (주)아모레퍼시픽
发明人： 김형준 , 김혁 , 성기사 , 김대권 , 성대석 , 박종희 , 조선아 , 김광미 , 이창훈 , 김정주
IPC分类号： A61K31/661 , C07K14/47 , C12Q1/68 , A61P17/00
CPC分类号： C12Q1/18 , G01N33/92 , G01N2405/08 , G01N2800/202 , A61K31/661 , C07K14/47
摘要： A sphingosylphosphorylcholine(SPC) antagonist is provided to prevent and treat diseases related to the expression decrease of anti-bacterial peptide such as atopic dermatitis, and screen the SPC antagonist by analyzing the expression recover of gene or protein of the anti-bacterial peptide. The sphingosylphosphorylcholine(SPC) antagonist manufactures the medicine for restoring the expression of anti-bacterial peptide back to the normal level in mammal requiring the expression restoration of anti-bacterial peptide. The screening method of the sphingosylphosphorylcholine(SPC) antagonist comprises the steps of: treating the object with sphingosylphosphorylcholine or its derivative to inhibit expression of anti-bacterial peptide; and treating the object with the SPC antagonist candidate material, and analyzing the expression restoration level of the anti-bacterial peptide in the object.
摘要翻译：提供鞘糖基磷酰胆碱（SPC）拮抗剂以预防和治疗与抗细菌肽如特应性皮炎的表达降低相关的疾病，并通过分析抗细菌肽的基因或蛋白质的表达恢复来筛选SPC拮抗剂。鞘氨醇磷酰胆碱（SPC）拮抗剂在需要抗菌肽表达恢复的哺乳动物中制备了将抗菌肽的表达恢复至正常水平的药物。鞘氨醇磷酰胆碱（SPC）拮抗剂的筛选方法包括以下步骤：用鞘糖基磷酰胆碱或其衍生物处理物体以抑制抗菌肽的表达; 并用SPC拮抗剂候选物质处理对象，分析对象中抗菌肽的表达恢复水平。

32. 发明公开

KR1020090009297A ＡＺＤ１１５２의 말레에이트 공결정 无效
标题翻译： AZD1152的MALEATE CO-CRYSTAL
公开(公告)号：KR1020090009297A
公开(公告)日：2009-01-22
申请号：KR1020087029569
申请日：2007-05-14
申请人： 아스트라제네카 아베
发明人： 세펜다,조쥐,조셉 , 스토레이,리차드
IPC分类号： C07D403/12 , A61K31/661 , A61P35/00 , C07F9/09
CPC分类号： C07D403/12 , C07F9/65583
摘要： The present invention relates to a novel co-crystal of 2-{cthyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-IH-pyrazol-3-yl)amino] quinazolin-7-yl}oxy)propyl]amino} ethyl dihydrogen phosphate (AZDl 152) which is an aurora kinase inhibitor that is useful in the treatment of hyperproliferative diseases such as cancer.
摘要翻译：本发明涉及一种新的2- {乙基[3 - （{4 - [（5- {2 - [（3-氟苯基）氨基] -2-氧代乙基} -1H-吡唑-3-基）氨基]喹唑啉-7-基}氧基）丙基]氨基}乙基二氢磷酸酯（AZD152），其是可用于治疗过度增殖性疾病如癌症的极光激酶抑制剂。

33. 发明公开

KR1020080108523A 지방 축적 억제제 无效
标题翻译： FAT累积抑制剂
公开(公告)号：KR1020080108523A
公开(公告)日：2008-12-15
申请号：KR1020087024439
申请日：2007-04-06
申请人： 유키지루시 메그밀크 가부시키가이샤
发明人： 타나카레오 , 이소가이토모유키 , 하루타유코 , 미우라스스무 , 카토켄 , 요시오카토시미츠 , 카와카미히로시 , 히구라시사토시 , 마츠야마히로아키
IPC分类号： A61K31/661 , A23L1/30 , A61K35/20 , A61P3/04
CPC分类号： A61K35/20 , A23L2/52 , A23L33/19 , A23V2002/00 , A61K31/661 , A23V2200/332 , A23V2250/1844
摘要： an agent for inhibiting the accumulation of a fat in an adipocyte, which comprises a milk-derived phospholipid as an active ingredient; a beverage/food for inhibiting the accumulation of a fat in an adipocyte, which contains a milk-derived phospholipid; an agent and a beverage/food for inhibiting the accumulation of a visceral fat, each of which comprises a phospholipid having sphingosine or a derivative thereof as an active ingredient; and an agent and a beverage/food for promoting the increase in blood adiponectin level and/or inhibiting the decrease in blood adiponectin level, each of which comprises a phospholipid having sphingosine or a derivative thereof as an active ingredient. ® KIPO & WIPO 2009
摘要翻译：用于抑制脂肪细胞中脂肪积聚的药剂，其包含作为活性成分的乳源磷脂; 用于抑制含有乳源磷脂的脂肪细胞中脂肪积聚的饮料/食物; 用于抑制内脏脂肪蓄积的药剂和饮料/食品，其中每一种包含具有鞘氨醇或其衍生物作为活性成分的磷脂; 以及用于促进血液中脂联素含量增加和/或抑制血液中脂联素水平降低的药剂和饮料/食品，其中每一种都包含具有鞘氨醇或其衍生物作为活性成分的磷脂。 ®KIPO＆WIPO 2009

34. 发明公开

KR1020070099700A 방법 无效
标题翻译：方法
公开(公告)号：KR1020070099700A
公开(公告)日：2007-10-09
申请号：KR1020077020674
申请日：2006-05-15
申请人： 듀폰 뉴트리션 바이오사이언시즈 에이피에스
发明人： 쿠마비제이 , 미아스니코브안드레이
IPC分类号： C12Q1/42 , A61K31/661 , A61K31/6615 , C07F9/09
CPC分类号： C12Q1/42 , C07F9/12
摘要： There is provided a method for the detection of phytase activity in a sample, which comprises bringing into association a phytase substrate and said sample, and measuring the level of of an organic metabolite of said phytase substrate.
摘要翻译：提供了一种用于检测样品中植酸酶活性的方法，其包括使肌醇六磷酸酶底物和所述样品结合，并测量所述植酸酶底物的有机代谢物的水平。

35. 发明公开

KR1020070000441A 경구 또는 비경구 약제로서의 원소 황 无效
标题翻译：元素硫作为口腔或外用医疗产品
公开(公告)号：KR1020070000441A
公开(公告)日：2007-01-02
申请号：KR1020067014922
申请日：2004-02-16
申请人： 아브달라, 마그드 아흐메드 코트브
发明人： 아브달라,마그드아흐메드코트브
IPC分类号： A61K33/04 , A61K31/661 , B30B5/02 , A61K31/10
CPC分类号： A61K31/10 , A61K31/661 , A61K33/04
摘要： Title element and its acid addition salts and derivatives are physiologically acceptable, essential and are readily converted to acceptable counter parts by established procedures, they are pharmacologically active on the liver, lungs, hematopoetic system and all body s ystems and a re thus useful when administered to warm blooded animals to induce detoxification of many endogenous and exogenous metabolites. They are useful in terminating diseases associated with Glutathione S Transferase and Epoxide Hydrolase disorders. These compounds are prepared as elemental or as salts or as acid addition salts and derivatives compounds. They are simply elemental or compounded into different dosage - multi form medicament compositions. ® KIPO & WIPO 2007
摘要翻译：标题元素及其酸加成盐和衍生物在生理上是可接受的，必需的，并且通过既定的方法容易地转化成可接受的对立部分，它们在肝，肺，造血系统和全身体系上具有药理活性，并且当给予温血动物，以诱导许多内源和外源代谢物的解毒。它们可用于终止与谷胱甘肽转移酶和环氧化物水解酶紊乱相关的疾病。这些化合物制备为元素或盐或作为酸加成盐和衍生物化合物。它们仅仅是元素的或复合成不同的剂量 - 多形式药物组合物。 ®KIPO＆WIPO 2007

36. 发明公开

KR1020050005569A 백혈병 치료방법 无效
标题翻译：如何治疗白血病
公开(公告)号：KR1020050005569A
公开(公告)日：2005-01-13
申请号：KR1020047021484
申请日：2000-03-28
申请人： 샤이어 캐나다 인코포레이티드
发明人： 고듀,헨리트 , 길레스,후란시스제이
IPC分类号： A61K31/513 , A61K31/357 , A61K31/661
CPC分类号： A61K31/675 , A61K31/506 , A61K31/70 , A61K31/704 , A61K38/13 , A61K38/1816 , A61K38/193 , A61K38/2013 , A61K38/202 , A61K38/212 , A61K38/32 , A61K39/39541 , A61K45/06 , A61K2035/124 , C12N5/0644 , C12N2501/03 , C12N2501/145 , A61K31/505 , A61K38/19 , A61K2300/00 , A61K38/20
摘要： 본 발명은 숙주에 있어서 백혈병 및 특히 급성 골수성 백혈병(acute myelogenous leukemia, AML)의 신규 치료 방법을 제공하고자 하는 것으로, 구조식(Ι)을 갖는 화합물의 치료학적 유효량을 숙주(host)에 투여하는 것으로 구성된다:

상기 식에서, B는 사이토신 또는 5-후루오로사이토신이고, R은 H, 모노포스페이트, 디포스페이트, 트리포스페이트,(C
1-6 알킬, C
2-6 알케닐, C
2-6 알키닐, C
6-10 아릴로 치환된 카보닐 및 (a)로 구성된 구룹중에서 선택되며, 상기식에서 각 RC는 독립적으로 H, C
1-6 알킬, C
2-6 알케닐, C
2-6 알키닐 및 하이드록시 보호그룹으로 구성된 그룹중에서 선택되고; 그리고 상기식에서 화합물은 실질적으로 (-)에난티오머형이다.

37. 发明公开

KR1020040051569A 라이소포스파티딘산의 치료학적 용도 无效
标题翻译：新陈代谢的新治疗方法
公开(公告)号：KR1020040051569A
公开(公告)日：2004-06-18
申请号：KR1020030090730
申请日：2003-12-12
申请人： 주식회사 바이오시너젠
发明人： 김영희 , 송동근 , 서홍원 , 허성오
IPC分类号： A61K31/661
CPC分类号： A61K31/661 , A61K31/00 , Y02A50/40 , Y02A50/401
摘要： PURPOSE: Provided is a novel therapeutical use of lysophosphatidic acid or its pharmaceutically acceptable salt. A composition containing lysophosphatidic acid or its pharmaceutically acceptable salt is useful for prevention and treatment of diseases associated with the accumulation of neutrophil. CONSTITUTION: A composition for prevention and treatment of inflammatory diseases caused by the accumulation of neutrophil is characterized by containing, as an active ingredient, lysophosphatidic acid represented by the formula(1) or (2), wherein R1 is C4-30 alkyl or C4-30 alkenyl having at least one or more double bonds or its pharmaceutically acceptable salt.
摘要翻译：目的：提供溶血磷脂酸或其药学上可接受的盐的新型治疗用途。含有溶血磷脂酸或其药学上可接受的盐的组合物可用于预防和治疗与嗜中性粒细胞积累相关的疾病。构成：用于预防和治疗嗜中性粒细胞积聚引起的炎性疾病的组合物的特征在于，含有式（1）或（2）所示的溶血磷脂酸作为活性成分，其中R1为C4-30烷基或C4 -30具有至少一个或多个双键的烯基或其药学上可接受的盐。

38. 发明公开

KR1020040034220A 라이소포스파티딜콜린 또는 그 유사체를 포함하는 패혈증예방 및 치료용 조성물 有权
标题翻译：包含赖氨酸衍生物或其衍生物的组合物用于预防和治疗食欲
公开(公告)号：KR1020040034220A
公开(公告)日：2004-04-28
申请号：KR1020020064308
申请日：2002-10-21
申请人： 주식회사 바이오시너젠
发明人： 김영희 , 송동근 , 서홍원 , 허성오
IPC分类号： A61K31/661
CPC分类号： Y02A50/40 , Y02A50/401
摘要： PURPOSE: Provided is a pharmaceutical composition for the prevention and treatment of sepsis is characterized by comprising, as an active ingredient, lysophosphatidylcholine or derivatives thereof. Therefore, the composition has excellent prevention and treatment effect on sepsis. CONSTITUTION: A pharmaceutical composition for the prevention and treatment of sepsis contains, as an active ingredient, lysophosphatidylcholine represented by the formula(1) or derivatives thereof represented by the formula(2). In the formula(1), R1 is C4-30 of alkyl group or C4-30 of alkenyl group having at least one double-bond, and in the formula(2), R2 is C4-30 alkyl group or C4-30 alkenyl group having at least one double bond.
摘要翻译：目的：提供用于预防和治疗败血病的药物组合物，其特征在于包含溶血卵磷脂或其衍生物作为活性成分。因此，该组合物对败血症具有优异的预防和治疗作用。构成：用于预防和治疗败血症的药物组合物含有由式（1）表示的溶血磷脂酰胆碱或由式（2）表示的其衍生物作为活性成分。在式（1）中，R 1为烷基的C 4-30或具有至少一个双键的烯基的C 4-30，并且在式（2）中，R 2为C 4-30烷基或C 4-30烯基具有至少一个双键的基团。

39. 发明公开

KR1020030048373A Ｎ-아실라이소포스파티딜콜린 화합물의 제조 방법 有权
标题翻译：生产N-羟基磷脂酰胆碱化合物和含有相同用于治疗代谢性骨髓疾病的药物组合物
公开(公告)号：KR1020030048373A
公开(公告)日：2003-06-19
申请号：KR1020020079874
申请日：2002-12-13
申请人： 전길자 , 김홍희 , 이장희 , 한소엽
发明人： 전길자 , 이장희 , 한소엽 , 김홍희 , 이은희 , 김영아 , 곽한복
IPC分类号： A61K31/661
CPC分类号： C07F9/10 , A61K31/14 , A61K31/16 , A61K31/6615 , C07F9/091
摘要： PURPOSE: Provided is a process of preparing an N-acyllysophosphatidylcholine compound which is excellent in inhibition of differentiation of osteoclast cells and has no toxicity. A pharmaceutical composition containing the N-acyllysophosphatidylcholine compound is useful in the prevention and treatment of metabolic bone disease. CONSTITUTION: A pharmaceutical composition for the prevention and treatment of metabolic bone disease contains N-acyl-o-phosphocholine-L-serine methylester compound of formula(1) or a pharmaceutically acceptable salt thereof alone or together with a pharmaceutically acceptable carrier. In formula, R is C14-20 saturated for unsaturated fatty acid. The metabolic bone disease is any one selected from the group consisting of osteoporosis, bone metastatic cancer lesions, a tumor formed primarily in bones, rheumatoid or degenerative arthritis, periodontal disease, alveolar bone resorption disease, inflammatory bone resorption disease and Paget's disease.
摘要翻译：目的：提供抑制破骨细胞分化且无毒性的N-酰基磷脂酰胆碱化合物的制备方法。含有N-酰基磷脂酰胆碱化合物的药物组合物可用于预防和治疗代谢性骨病。构成：用于预防和治疗代谢性骨疾病的药物组合物单独或与药学上可接受的载体一起含有式（1）的N-酰基-O-磷酸胆碱-L-丝氨酸甲酯化合物或其药学上可接受的盐。在式中，对于不饱和脂肪酸，R为饱和的C14-20。代谢性骨病是选自骨质疏松症，骨转移性癌症病变，主要在骨形成的肿瘤，类风湿性关节炎，退行性关节炎，牙周病，牙槽骨吸收疾病，炎性骨吸收疾病和佩吉特氏病等中的任意一种。

40. 发明公开

KR1020020087456A 혈관 손상 활성을 지닌 조합 요법 无效
标题翻译：组合治疗与血管破坏活动
公开(公告)号：KR1020020087456A
公开(公告)日：2002-11-22
申请号：KR1020027013061
申请日：2001-03-27
申请人： 앤지오젠 파마슈티칼스 리미티드
发明人： 데이비스피터데이비드 , 도허티그레임
IPC分类号： A61K31/661
CPC分类号： A61K31/661 , A61K31/66 , A61K33/24 , A61K41/0038 , A61K31/555 , A61K31/335 , A61K2300/00
摘要： 본발명은다음의요법, 즉 (i) 이온화방사선, (ii) 백금항종양제, 및 (iii) 탁산중 하나의유효량투여이전에, 이후에또는동시에하기화학식의 ZD6126 또는이것의약학적으로허용가능한염의유효량을사람과같은온혈동물에게투여하는단계를포함하는상기동물에서혈관손상효과의생성방법을제공한다. 본발명은또한사람과같은온혈동물에서혈관손상효과의생성에사용하기위한약제의제조에있어서 ZD6126 및상기요법중 하나의용도에관한것이고, ZD6126 및백금항종양제와탁산중 하나를포함하는각각의약학조성물및 키트에관한것이다.
摘要翻译：本发明涉及一种在温血动物如人中产生血管损伤作用的方法，该方法包括向所述动物施用有效量的ZD6126或其药学上可接受的盐，在其之前或之后有效量的以下疗法之一：i）电离辐射; ii）铂抗肿瘤剂; 和iii）紫杉烷。本发明还涉及ZD6126的应用和上述疗法之一，用于制造用于在温血动物（例如人）中产生血管损伤作用的药物，以及药物组合物和试剂盒，其各自包含ZD6126 和铂抗肿瘤剂和紫杉烷之一

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式